Will marijuana be rescheduled?
Short Answer
Marijuana rescheduling is considered likely before October 1, 2027, despite an ongoing administrative stay by the DEA Chief Administrative Law Judge that introduces broader delays and reduces the probability of earlier resolutions. The market prices this outcome at 72.0%, diverging from the model's 54.2%.
1. Market Behavior & Drivers
The perceived probability of marijuana rescheduling collapsed following a September 29, 2026, order from a DEA Chief Administrative Law Judge. The order paused the federal rulemaking process to allow for consideration of a new Government Accountability Office (GAO) report. The market, which had priced the odds at 23.0% on September 27, fell to 6.0% by October 3 in direct response to this administrative stay.
Since the initial drop, the contract has traded in a narrow, low-probability range. The current price of 7.0% indicates that the market has priced in a significant, indefinite delay to the rescheduling process. No other developments appear to have influenced pricing during the period.
- Since last update (~24h): Model's headline probability dropped -37.8pp; with market flat, edge flipped to -12.8pp (model_led).
- Model conviction for resolution before Apr 1, 2027, plummeted -81.5pp, widening its edge (model_led).
- Overall model confidence decreased -1.0pp, reflecting reduced probabilities for earlier resolutions.
- Broad rescheduling before April 2027 appears unlikely, given the ongoing administrative stay.
- Resolution by July 2027 appears less likely with typical 18-36 month DEA timelines.
- Later deadlines, such as October 2027 or January 2028, allow time for procedural hurdles.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Before Jan 1, 2027 | 7.0% | 3.5% | An administrative stay makes completion by January 2027 highly improbable due to lengthy procedures. |
| Before Apr 1, 2027 | 15.0% | 7.5% | An administrative stay and appellate court briefing extending into February 2027 reduce likelihood. |
| Before Jul 1, 2027 | 68.0% | 45.6% | An administrative pause and lengthy DEA scheduling timelines make resolution by July 2027 less likely. |
| Before Oct 1, 2027 | 72.0% | 54.2% | The administrative process is paused, delaying potential resolution timelines. |
| Before Jan 1, 2028 | 67.0% | 54.2% | The administrative stay causes delays, but this longer timeframe allows more opportunity to overcome hurdles. |
Current Context
Federal rulemaking for broader marijuana rescheduling is paused. As of October 11, 2026, the federal process to reschedule all marijuana to Schedule III is under an administrative stay [1][2][3]. DEA Chief Administrative Law Judge Derek C. Julius ordered this pause on September 29, 2026, to consider admitting a new Government Accountability Office (GAO) report into the hearing record [2][3][4]. The government's response to this motion is due by October 13, 2026 [2][3][4].
Specific cannabis products are already rescheduled, but broader efforts face delays. President Trump's April 2026 order reclassified FDA-approved cannabis products and state-licensed medical marijuana products from Schedule I to Schedule III [5][6][7]. These products are now officially rescheduled. Prediction markets, such as Polymarket, indicate approximately 4% confidence as of October 11, 2026, that the broader, total rescheduling of all marijuana will finalize by the end of 2026 [8][9]. This reflects ongoing legal and regulatory delays [8][9]. An appellate court is also weighing consolidated lawsuits that seek to block the broader rescheduling effort, with a briefing schedule extending into February 2027 [5].
Sources (9)
- 1DEA Pauses Marijuana Reschedule to Consider New GAO Reportnatlawreview.com
- 2DEA Judge Pauses Marijuana Rescheduling: What the October 13 Deadline Means | Budpediabudpedia.com
- 3Pending Marijuana Rescheduling Put on Hold | Regulatory Oversightregulatoryoversight.com
- 4Marijuana Rescheduling: Trump's Kessler Move Markets Missed | StockAlpha.aistockalpha.ai
- 5Feds And Marijuana Opponents Agree On Briefing Schedule In Lawsuit Challenging Trump's Reclassification Move - Marijuana Momentmarijuanamoment.net
- 6Justice Department Places FDA-Approved Marijuana...justice.gov
- 7Federal Marijuana Rescheduling: Process and Impact | Moritz College of Lawmoritzlaw.osu.edu
- 8Weed rescheduled by December 31 76% No · Polymarketexplorer.struct.to
- 9DOJ finalizes cannabis rescheduling to Schedule III, market reacts with cautioncryptobriefing.com
2. Price Chart
Historical Price (Probability)
Outcome probability
Date
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
Outcome: Before Apr 1, 2027
📉 October 10, 2026: 79.0pp drop
Price decreased from 94.0% to 15.0%
What happened: The primary driver of the 79 percentage point drop in the "Will marijuana be rescheduled? Before Apr 1, 2027" market on October 10, 2026, was news of procedural delays that significantly reduced the likelihood of meeting the tight deadline [1][2]. Specifically, the DEA Chief Administrative Law Judge temporarily stayed the broad Schedule I-to-III proceeding on September 29, 2026, to consider a new Government Accountability Office report [3][4][5]. This administrative halt, combined with a separate D.C. Circuit challenge that has a proposed briefing schedule extending through February 19, 2027, made a legally effective broad rescheduling before April 1, 2027, difficult [6][7]. Social media activity was irrelevant, as no related posts or viral narratives from influential figures were identified that contributed to this market movement.
📈 October 09, 2026: 72.0pp spike
Price increased from 22.0% to 94.0%
What happened: The primary driver of the 72.0 percentage point spike on October 9, 2026, appears plausibly tied to news regarding executive pressure to accelerate marijuana rescheduling [8]. While the "Trump" tag is relevant, and "Trump's Kessler Move" is mentioned in connection to rescheduling, the available reporting does not establish a definitive single social-media catalyst for this specific movement [8]. Although litigation schedules indicated difficulty for broad rescheduling before April 1, 2027, the perceived executive pressure likely fueled the temporary surge [7]. Consequently, social media was not a primary driver of this price movement, as no specific viral narrative or key post was identified [8].
Outcome: Before Oct 1, 2027
📈 October 08, 2026: 54.0pp spike
Price increased from 1.0% to 55.0%
What happened: The provided web research does not identify a clear primary driver for the 54.0 percentage point spike in the "Will marijuana be rescheduled? Before Oct 1, 2027" market on October 8, 2026 [9]. There is no evidence of social media activity from key figures or viral narratives discussing marijuana rescheduling on or immediately preceding this date that would explain the surge [10][11][12]. Traditional news from October 8, 2026, explicitly indicated procedural delays in the broader DEA rescheduling process rather than a completed decision, which contradicts a market spike [13][8][14]. Therefore, based on the available sources, social media appears irrelevant to this specific price movement, and traditional news suggests a contradictory trend.
Outcome: Before Jan 1, 2027
📉 September 29, 2026: 16.6pp drop
Price decreased from 21.0% to 4.4%
What happened: The primary driver of the 16.6 percentage point drop on September 29, 2026, was the DEA Chief Administrative Law Judge's decision to stay the marijuana rescheduling proceeding [15]. This procedural pause, enacted to consider opponents' request to incorporate a GAO report detailing "gaps" in federal drug-scheduling processes, significantly increased timeline risk for rescheduling by January 1, 2027 [15]. Although a Trump senior adviser reported on September 29 that President Trump was unhappy with the delays and intended to push for acceleration, this was a traditional news report reacting to the stay and did not cause the market's negative reassessment of the immediate timeline [16]. Social media activity was irrelevant to this price movement, which was directly attributable to the official administrative action [15].
Sources (16)
- 1Will marijuana be rescheduled? Odds & Predictionskalshi.com
- 2Live odds: Will marijuana be rescheduled? | ElectionOddselectionodds.live
- 3DEA Pauses Marijuana Reschedule to Consider New GAO Reportnatlawreview.com
- 4Marijuana Rescheduling Put On Hold Again By DEA420magazine.com
- 5Pending Marijuana Rescheduling Put on Hold | Regulatory Oversightregulatoryoversight.com
- 6DOJ and Rescheduling Opponents Propose D.C. Circuit Briefing Schedule Into 2027cannabisnews.org
- 7Feds And Marijuana Opponents Agree On Briefing Schedule In Lawsuit Challenging Trump's Reclassification Move - Marijuana Momentmarijuanamoment.net
- 8Marijuana Rescheduling: Trump's Kessler Move Markets Missed | StockAlpha.aistockalpha.ai
- 9Will marijuana be rescheduled? Odds | Kalshi & Polymarketpredictmarketcap.com
- 10Trump, Xi Prepare for High-Stakes Meeting; Oil Extends Decline | Bloomberg Daybreak: US Editionyoutube.com
- 11Trump Says He’ll Meet Xi Twice More This Year | Bloomberg Businessweekyoutube.com
- 12Trump, Xi Thrust Fierce US-China AI Rivalry Into Spotlight | Bloomberg Businessweekyoutube.com
- 13State officials push DEA for cannabis rescheduling guidance (Newsletter: October 8, 2026) - Marijuana Momentmarijuanamoment.net
- 14Cannabis And The Midterm Elections - Constitutional & Administrative Law - United Statesmondaq.com
- 15DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing 'Gaps' In Federal Processes - Marijuana Momentmarijuanamoment.net
- 16President Trump ‘Not Happy’ With Marijuana Rescheduling Delays, Plans to Contact Attorney General and DEA Chief, Senior Adviser Saysthemarijuanaherald.com
4. Market Data
Contract Snapshot
A "Yes" resolution occurs if marijuana is officially rescheduled under US federal law by the specified deadline for each market. A "No" resolution occurs if marijuana is not officially rescheduled by that deadline. Key deadlines for these markets are April 1, 2027, July 1, 2027, and January 1, 2028.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Before Jan 1, 2027 | $0.07 | $0.93 | 7% |
| Before Apr 1, 2027 | $0.49 | $0.74 | 15% |
| Before Jul 1, 2027 | $0.68 | $0.65 | 68% |
| Before Oct 1, 2027 | $0.87 | $0.40 | 72% |
| Before Jan 1, 2028 | $0.70 | $0.32 | 67% |
| Before Jan 20, 2029 | $0.80 | $0.23 | 81% |
Market Discussion
As of October 11, 2026, the Trump administration has placed state-licensed medical marijuana and FDA-approved products in Schedule III, but broader marijuana rescheduling from Schedule I is still undergoing a separate DEA rulemaking and hearing process [1][2][3]. Prediction-market traders currently price broader rescheduling as likely but delayed, with approximately 81% odds before January 20, 2029, as of October 11, 2026 [4][5]. Bullish commentators argue that President Trump's pressure and adviser appointments favor eventual completion, despite a September 29 pause in the process being viewed as a meaningful delay risk, while political and legal opposition also persists [6][7][8][9].
Sources (9)
- 1Marijuana Rescheduling Regulatory Actions | DEA.govdea.gov
- 2Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirementsjustice.gov
- 3Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
- 4Will marijuana be rescheduled? Odds | Kalshi & Polymarketpredictmarketcap.com
- 5Will marijuana be rescheduled? - Kalshi KXMJSCHEDULE Odds | CoinRithmcoinrithm.com
- 6Kalshi Marijuana Rescheduling Odds: A Judge With No Deadline | OddsShopperoddsshopper.com
- 7Marijuana Rescheduling: Trump's Kessler Move Markets Missed | StockAlpha.aistockalpha.ai
- 8GOP Congressman Says Marijuana Rescheduling Should Expand To 'Across-The-Board' Review Of Psychedelics And Other Drugs - Marijuana Momentmarijuanamoment.net
- 9Federal Court Lets Trump Move Ahead With Marijuana Rescheduling, Rejecting Pharma Company And Drug Testing Industry Request To Block It ⋆ Patriots Hemppatriotshemp.com
5. Trust Index
Largest single print on KXMJSCHEDULE-27 carried 53% of its $1,881 tape (window is 100% of 24h flow; print is 2d old)
Integrity risk· Large trades
How it adds up
Integrity80% of score81Good
Trade quality20% of score54Caution
Includes the cost to trade: a $10,000 order can't be filled here because the order book is too thin.
Trust score75Good
Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index
Trust profile
Integrity4 screens run · 6 don't apply
6. What specific procedural hurdles must the DEA overcome to finalize rescheduling, and what is the projected timeline for each step following the October 2026 administrative stay?
| Hearing Window | June 29–July 15, 2026 [1][2] |
|---|---|
| Optimistic Decision Projection | Late 2026 [3][1] |
| Final Rule Effective Period | 30 days [3][4][5] |
The DEA's rescheduling process faces significant procedural hurdles following an administrative stay. An administrative stay issued in October 2026 has necessitated a restarted process, distinct from a new substantive rulemaking step, to ensure compliance with the Administrative Procedure Act (APA), Controlled Substances Act, and DEA regulations [6][5][2]. The initial stages involve a procedural reset and participant qualification. This includes the DEA issuing a new hearing notice, receiving notices of intention to participate, assessing standing, selecting participants, and assigning an administrative-law judge [1][2]. The public schedule currently sets the evidentiary hearing to occur between June 29 and July 15, 2026, though this is subject to potential continuances [1][2].
Following the hearing, the DEA Administrator must make a crucial rescheduling decision. After the evidentiary hearing concludes and subsequent briefing or a recommended decision is submitted, the DEA Administrator is required to review the complete record [3][1]. The Administrator will then decide whether to adopt, modify, or reject the proposed rescheduling of marijuana [3][1]. While there is no binding statutory deadline for this determination, an optimistic projection places this decision in late 2026; however, historical insights suggest it could potentially extend into 2027 [3][1]. Subsequently, the DEA and Department of Justice (DOJ) will need to issue and publish a final rule that broadly addresses marijuana. This broader rule is distinct from the April 28, 2026 final rule, which only covered limited products [3][4][5]. A general final rule typically becomes effective after a 30-day period [3][4][5].
Judicial review represents the final and potentially most significant challenge. Once the final rule is published, interested parties have the right to challenge it in federal court [3][4]. This judicial review serves as the ultimate procedural hurdle, with the potential to significantly delay or even suspend the final rule's effective operation [3][4]. Such challenges could keep broader marijuana rescheduling from being legally implemented until the court proceedings are resolved [3][4].
Sources (6)
- 1Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
- 2FOR FURTHER INFORMATION CONTACT:federalregister.gov
- 3Will Marijuana Be Rescheduled? The Latest on Schedule III - LegalClaritylegalclarity.org
- 4Will Marijuana Be Rescheduled? Kalshi Odds & Analysisactionnetwork.com
- 5FOR FURTHER INFORMATION CONTACT:federalregister.gov
- 6https://www.federalregister.gov/documents/full_text/text/2026/04/28/2026-08178.txtfederalregister.gov
7. What factors are driving the low single-digit probabilities on prediction markets like Polymarket for a final rescheduling rule before 2027?
| Probability by Jan 1, 2027 | 7–8% (October 11, 2026) [1][2] |
|---|---|
| Probability by mid/late 2027 or Jan 2028 | 68–72% (October 11, 2026) [1][2] |
| DEA Hearing Schedule | June 29–July 15, 2026 [3][4][5] |
Prediction markets assign low probabilities to imminent marijuana rescheduling. As of October 11, 2026, prediction markets like Polymarket indicated only a 7–8% chance of a final rescheduling rule being completed by January 1, 2027 [1][2]. This low probability stands in stark contrast to the 68–72% probability for completion by mid/late 2027 or January 2028, suggesting that traders view a final rule as unlikely within the remaining 2026 timetable due to the complex, multi-stage administrative process required [1][2].
The rescheduling process involves a lengthy, multi-stage administrative review. The April 2026 Department of Justice (DOJ) action was limited in scope, moving only FDA-approved and state-licensed medical marijuana to Schedule III, while leaving recreational marijuana and broader cannabis in Schedule I [3][6]. This partial rule did not settle the broader question, as prediction market contracts generally require marijuana itself to be legally removed from Schedule I [3][6]. Consequently, comprehensive rescheduling was restarted via a formal DEA administrative hearing, scheduled from June 29–July 15, 2026. This hearing involves specific participant selection, evidentiary submissions, testimony, cross-examination, and ultimately a decision by the DEA Administrator before a final rule can be issued. Following the DOJ's limited medical-only rule and the announcement of the new hearing, the market repriced, indicating a fresh and longer administrative process rather than imminent comprehensive action [3][4][5].
Post-hearing procedures and legal risks further delay effective rescheduling. Even after a favorable administrative decision, the agency must publish a final rule and adhere to implementation procedures, which typically include a 30-day effectiveness period and potential federal-court challenges or stays [7][3][4]. This procedural timeline makes a legally effective rule before year-end 2026 particularly challenging. Furthermore, prediction markets typically resolve "Yes" only when marijuana is actually removed from Schedule I by the deadline, not merely upon an announcement or Federal Register publication [8][3][4]. Therefore, risks related to the timing of announcement, legal effectiveness, and potential litigation collectively depress the near-term probability of rescheduling [8][3][4].
Sources (8)
- 1Will marijuana be rescheduled? Odds & Predictionskalshi.com
- 2Weed rescheduled by which date? - Quote su Polymarket | CoinRithmcoinrithm.com
- 3Marijuana Rescheduling Regulatory Actionsdea.gov
- 4FEDERAL MARIJUANA RESCHEDULING EXPLAINERdrugpolicy.org
- 5Cannabis Rescheduling Arrives, With Limitslegal500.com
- 6Rescheduling Medical Marijuana: Implications for Criminal...congress.gov
- 7Will Marijuana Be Rescheduled? The Latest on Schedule III - LegalClaritylegalclarity.org
- 8Will marijuana be rescheduled? - Kalshi KXMJSCHEDULE Odds | CoinRithmcoinrithm.com
8. How does President Trump's completed April 2026 rescheduling of specific FDA-approved products differ from the broader, currently-stalled DEA proposal to reschedule all marijuana?
| Completed Rescheduling Scope | Limited categories of FDA-approved and state-licensed medical marijuana products (April 22-23, 2026) [1][2][3][4][5][6] |
|---|---|
| Immediate Action Authority | Acting Attorney General's authority under Controlled Substances Act section 811(d)(1) [1][2][4][5] |
| Broader Rescheduling Status | Stalled, new hearing scheduled for June 29, 2026 [1][2][5][7] |
In April 2026, the Trump administration enacted a limited marijuana rescheduling. Through the Department of Justice (DOJ) and Drug Enforcement Administration (DEA), specific FDA-approved drug products containing marijuana, along with marijuana subject to a qualifying state medical-marijuana license, were moved to Schedule III of the Controlled Substances Act [1][2][3][4][5][6]. This immediate change, which took effect on April 22–23, 2026, leveraged the Acting Attorney General’s authority under CSA section 811(d)(1) to fulfill U.S. treaty obligations, thereby bypassing the typical full rulemaking process for these particular categories [1][2][4][5].
This limited action differs significantly from a broader, stalled rescheduling proposal. The April 2026 order did not include the broader rescheduling of the marijuana plant itself or all cannabis products; recreational/adult-use marijuana, unlicensed bulk marijuana, and other materials outside the specified categories remained in Schedule I [1][2][3][4][5][6]. A separate, more comprehensive proposal to generally move marijuana from Schedule I to Schedule III is currently stalled. For this extensive rescheduling effort, which would still necessitate extensive administrative processes and likely face judicial challenges, the DEA has issued a new notice of hearing, with proceedings scheduled to commence on June 29, 2026 [1][2][5][7][4][6]. The limited April 2026 order is distinct from any comprehensive federal rescheduling or legalization [1][2][4][7][6].
Sources (7)
- 1Justice Department Places FDA-Approved Marijuana...justice.gov
- 2Marijuana Rescheduling Regulatory Actionsdea.gov
- 3DEA Reschedules FDA-Approved Marijuana Products and...saul.com
- 4Federal marijuana rescheduling arriveshlc.com
- 5Federal Marijuana Rescheduling: Process and Impactmoritzlaw.osu.edu
- 6Marijuana rescheduling: Trump eases rules on medical...npr.org
- 7Will Marijuana Be Rescheduled? The Latest on Schedule III - LegalClaritylegalclarity.org
9. What historical data is available on the typical timeline for the DEA to advance a substance from a notice of proposed rulemaking to a final, legally-binding rule?
| Uncontested Scheduling | 4-9 months [1][2][3] |
|---|---|
| Contested Scheduling (General) | 18-36 months or several years [3] |
| Marijuana Scheduling (Historical Extreme) | Up to 22 years [3] |
Uncontested DEA scheduling rules typically finalize within nine months. Permanent scheduling rules, when uncontested, generally become final within 4 to 9 months following a notice of proposed rulemaking (NPRM) [1][2][3]. This standard process includes a public-comment period, usually 30 days, followed by agency review and drafting of the final regulations [4][5]. Recent instances demonstrate this timeline, such as fentanyl-related substances being finalized in approximately 8.6 months [1] and diphenidine in about 3.9 months [2].
Contested scheduling, especially marijuana, significantly extends DEA timelines. Cases involving formal hearings, administrative law judge (ALJ) recommendations, and potential litigation can prolong the timeline to between 18 and 36 months, or even several years [3]. Marijuana presents an exceptionally slow and procedurally complex history. Historical petitions for marijuana scheduling illustrate that contested cases can span roughly four to eight years, with one specific case from 1972 not concluding until 1994, a duration of 22 years [3]. The broad Schedule I-to-III NPRM for marijuana, published on May 21, 2024, encountered formal proceedings delays and restarts in 2026 [6]. A replacement hearing occurred from June 29 to July 15, 2026, and as of September 24, 2026, the ALJ recommendation was still pending [7]. Given these complexities, achieving a legally binding broad rescheduling before October 11, 2026, would necessitate an exceptionally expedited resolution [3]. The final rule issued on April 28, 2026, did not broadly reschedule marijuana [8][9].
Sources (9)
- 1Federal Register:: Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule Ifederalregister.gov
- 2FOR FURTHER INFORMATION CONTACT:federalregister.gov
- 3Where do efforts to legalize, reschedule marijuana stand? | WFXRtvwfxrtv.com
- 4United States Drug Enforcement Administrationdea.gov
- 5DEA Announces Proposed Rules for Permanent Telemedicine Flexibilitiesdea.gov
- 6DEA Hearing on Proposed Marijuana Rescheduling...dea.gov
- 7High Time for a Change? Post–DEA Hearing, Broader...morganlewis.com
- 8Schedules of Controlled Substances: Rescheduling...federalregister.gov
- 9Marijuana Rescheduling Regulatory Actions | DEA.govdea.gov
10. What are the primary legal arguments being made in the appellate court lawsuits seeking to block marijuana rescheduling, and how does the briefing schedule extending into February 2027 impact the market's resolution?
| Appellate Schedule Endpoint | February 19, 2027 [1][2] |
|---|---|
| DOJ Order Date | April 22, 2026 [2][3][4] |
| Merits Decision Expectation | Unlikely before mid-2027 [1][2] |
Appellate lawsuits challenge marijuana rescheduling based on procedural and constitutional grounds. The D.C. Circuit is currently reviewing three consolidated challenges to the Department of Justice's April 22, 2026, order, which moved specific marijuana drug products to Schedule III while other marijuana products remained in Schedule I [2][3][4]. Petitioners primarily assert procedural and statutory violations, alleging breaches of the Administrative Procedure Act and Controlled Substances Act by bypassing required notice-and-comment procedures and an administrative hearing, and by issuing the order without sufficient evidentiary support [3][4][5]. Challenges also include constitutional objections to administrative-law-judge removal restrictions, arguing they conflict with separation-of-powers and Article II principles [4][5]. Despite these challenges, the D.C. Circuit rejected requests to freeze the April order, meaning the limited Schedule III classification remains in effect while the case proceeds [1][2].
An extended appellate timeline delays comprehensive marijuana rescheduling until at least mid-2027. The proposed appellate schedule for the D.C. Circuit extends through February 19, 2027, with key briefing deadlines set for November 24, 2026 (petitioners' opening brief), January 13, 2027 (government's response), and February 5, 2027 (petitioners' reply) [1][2]. Consequently, a merits decision from the D.C. Circuit is not anticipated before mid-2027 [1][2]. For prediction markets, the relevant event for full resolution is the legally effective removal of all marijuana from Schedule I, which the April order does not fully satisfy [6][2]. The extended appellate timeline, combined with a separate ongoing administrative process by the DEA that began June 29, 2026, introduces significant delays, making it possible that a full-market resolution for comprehensive rescheduling will not occur until after mid-2027 or even later [7][6][2][8].
Sources (8)
- 1U.S. Marijuana Rescheduling Challenge Could Reach Oral Arguments in 2027thcfarmer.com
- 2DOJ and Rescheduling Opponents Propose D.C. Circuit Briefing Schedule Into 2027cannabisnews.org
- 3D.C. Circuit Challenge And DEA Hearing Put Federal Cannabis Rescheduling To The Test - - United Statesmondaq.com
- 426-1136app.accessnewswire.com
- 526-1136files.iowamedicalmarijuana.org
- 6Will marijuana be rescheduled? Odds & Predictionskalshi.com
- 7Will Marijuana Be Rescheduled? The Latest on Schedule III - LegalClaritylegalclarity.org
- 8DEA Hearing on Proposed Marijuana Rescheduling...dea.gov
11. What Could Change the Odds
Key Catalysts
Broad nationwide rescheduling of marijuana from Schedule I to Schedule III remains stayed as Chief ALJ Derek Julius considers whether to admit a September 2026 GAO report and allow supplemental briefing; government and participant responses are due October 13, 2026 [1][2][3][4]. This broad rescheduling hearing ran from June 29 through July 15, 2026, pursuant to President Trump's December 18, 2025 Executive Order 14370, which directed the Attorney General to complete Schedule III rulemaking expeditiously [5][6]. A separate April 2026 DOJ order already moved FDA-approved marijuana products and marijuana covered by qualifying state medical licenses into Schedule III, an order whose stay the D.C. Circuit denied, leaving it effective while merits litigation proceeds [1][2][7]. The proposed litigation schedule for this limited order sets petitioners’ opening briefs for November 24, 2026, the government response for January 13, 2027, and final briefs for February 19, 2027, making a merits decision unlikely before mid-2027 [1][2].
Bullish catalysts include a favorable ALJ recommendation, DEA adoption of broad Schedule III, Trump/DOJ prioritization, and court acceptance of the April order [3][4][8]. Conversely, bearish catalysts are the GAO procedural challenge, supplemental briefing, adverse ALJ or DEA findings, D.C. Circuit vacatur of the April order, congressional or administrative opposition, and delays extending beyond the 2026 midterms [3][4][8]. Prediction market snapshots on October 11, 2026, price eventual rescheduling before January 20, 2029, at about 81%, before October 1, 2027, at about 72%, before July 1, 2027, at about 68%, before January 1, 2028, at about 67%, and before April 1, 2027, at about 15%; before January 1, 2027, is about 7% [9][10]. Market interpretation is strongly time-horizon dependent: near-term full rescheduling is viewed skeptically due to extended hearing, administrative review, and litigation timelines, while eventual passage by the end of Trump’s term remains favored because the administration has issued an expedited-rescheduling directive and taken partial action [8].
Potential industry catalysts from Schedule III status include relief from Internal Revenue Code Section 280E’s tax treatment, easier institutional capital access, and greater federal-regulatory alignment, though these benefits depend on the exact scope and legal effectiveness of the final rule [8]. The base-case forecast as of October 11, 2026, holds that limited medical/FDA Schedule III status persists in the near term; broad marijuana rescheduling is unlikely before year-end 2026 and is more plausibly a 2027-2028 event if the stayed proceeding resumes and the administration completes rulemaking [1][2][3]. The April order’s court challenge creates a separate risk of partial rollback [1][2][3].
Key Dates & Catalysts
- Expiration: January 08, 2027
- Closes: January 20, 2029
Sources (10)
- 1DOJ and Rescheduling Opponents Propose D.C. Circuit Briefing Schedule Into 2027cannabisnews.org
- 2Feds And Marijuana Opponents Agree On Briefing Schedule In Lawsuit Challenging Trump's Reclassification Move - Marijuana Momentmarijuanamoment.net
- 3"Marijuana" Rescheduling Delayed, Again. What It Could Mean, and What Comes Nextharris-sliwoski.com
- 4Marijuana Rescheduling Put On Hold Again By DEA420magazine.com
- 5Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
- 6FOR FURTHER INFORMATION CONTACT:federalregister.gov
- 7D.C. Circuit Denies Stay of Schedule III Marijuana Order (No. 26-1106)cannabisregulations.ai
- 8Will Marijuana Be Rescheduled? Kalshi Odds & Analysisactionnetwork.com
- 9Will marijuana be rescheduled? Odds | Kalshi & Polymarketpredictmarketcap.com
- 10Will marijuana be rescheduled? - Kalshi KXMJSCHEDULE Odds | CoinRithmcoinrithm.com
13. Related News
Last updated: October 11, 2026, 12:12 UTC
DEA Judge's Stay on Rulemaking Pushes Marijuana Rescheduling Odds Lower
A late September order from a Drug Enforcement Administration (DEA) judge to stay the formal hearing process for rescheduling marijuana has driven a significant repricing in prediction markets, with t...
Last updated: October 11, 2026, 12:12 UTC
DEA Hearing Stay Pushes Marijuana Rescheduling Timeline Bets Into 2027
A procedural halt in the Drug Enforcement Administration's hearing on marijuana rescheduling has pushed traders to price in a delayed timeline, with contracts for an early 2027 reclassification seeing...
Last updated: October 11, 2026, 12:12 UTC
Marijuana Rescheduling Market Pushes Out Timeline After DOJ Action
Probabilities for a near-term, comprehensive federal rescheduling of marijuana fell sharply on Thursday, April 23, 2026, after the Department of Justice (DOJ) announced a final order that reclassified...
Last updated: October 11, 2026, 12:12 UTC
Marijuana Rescheduling Timeline Compresses Sharply on DOJ News
Prediction markets tracking the federal rescheduling of marijuana saw a sharp, positive repricing on Wednesday, April 22, 2026, as all contracts moved toward a significantly accelerated timeline. The ...
